X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/doer-biologics-announces-first-subject-dosed-in-phase-i-12-week-multiple-ascending-dose-mad-clinical-trial-of-dr10624-and-received-ind-approval-from-nmpa-301890125.html